These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 38822803)

  • 1. Decoding Inhibitor Egression from Wild-Type and G2019S Mutant LRRK2 Kinase: Insights into Unbinding Mechanisms for Precision Drug Design in Parkinson's Disease.
    Naskar A; Roy RK; Srivastava D; Patra N
    J Phys Chem B; 2024 Jul; 128(28):6657-6669. PubMed ID: 38822803
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structural insight into G2019S mutated LRRK2 kinase and brain-penetrant type I inhibitor complex: a molecular dynamics approach.
    Naskar A; Bhanja KK; Roy RK; Patra N
    J Biomol Struct Dyn; 2023 Sep; ():1-21. PubMed ID: 37702159
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular Modeling Study on the Interaction Mechanism between the LRRK2 G2019S Mutant and Type I Inhibitors by Integrating Molecular Dynamics Simulation, Binding Free Energy Calculations, and Pharmacophore Modeling.
    Tan S; Zhang Q; Wang J; Gao P; Xie G; Liu H; Yao X
    ACS Chem Neurosci; 2022 Mar; 13(5):599-612. PubMed ID: 35188741
    [TBL] [Abstract][Full Text] [Related]  

  • 4. LRRK2 G2019S-induced mitochondrial DNA damage is LRRK2 kinase dependent and inhibition restores mtDNA integrity in Parkinson's disease.
    Howlett EH; Jensen N; Belmonte F; Zafar F; Hu X; Kluss J; Schüle B; Kaufman BA; Greenamyre JT; Sanders LH
    Hum Mol Genet; 2017 Nov; 26(22):4340-4351. PubMed ID: 28973664
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preclinical modeling of chronic inhibition of the Parkinson's disease associated kinase LRRK2 reveals altered function of the endolysosomal system in vivo.
    Kluss JH; Mazza MC; Li Y; Manzoni C; Lewis PA; Cookson MR; Mamais A
    Mol Neurodegener; 2021 Mar; 16(1):17. PubMed ID: 33741046
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Type II kinase inhibitors show an unexpected inhibition mode against Parkinson's disease-linked LRRK2 mutant G2019S.
    Liu M; Bender SA; Cuny GD; Sherman W; Glicksman M; Ray SS
    Biochemistry; 2013 Mar; 52(10):1725-36. PubMed ID: 23379419
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of G2019S-Selective Leucine Rich Repeat Protein Kinase 2 inhibitors with in vivo efficacy.
    Leśniak RK; Nichols RJ; Schonemann M; Zhao J; Gajera CR; Fitch WL; Lam G; Nguyen KC; Smith M; Montine TJ
    Eur J Med Chem; 2022 Feb; 229():114080. PubMed ID: 34992038
    [TBL] [Abstract][Full Text] [Related]  

  • 8. LRRK2 kinase inhibitors reduce alpha-synuclein in human neuronal cell lines with the G2019S mutation.
    Zhao Y; Keshiya S; Perera G; Schramko L; Halliday GM; Dzamko N
    Neurobiol Dis; 2020 Oct; 144():105049. PubMed ID: 32800998
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential Inhibition of LRRK2 in Parkinson's Disease Patient Blood by a G2019S Selective LRRK2 Inhibitor.
    Bright JM; Carlisle HJ; Toda AMA; Murphy M; Molitor TP; Wren P; Andruska KM; Liu E; Barlow C
    Mov Disord; 2021 Jun; 36(6):1362-1371. PubMed ID: 33836114
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting leucine-rich repeat kinase 2 (LRRK2) for the treatment of Parkinson's disease.
    Domingos S; Duarte T; Saraiva L; Guedes RC; Moreira R
    Future Med Chem; 2019 Aug; 11(15):1953-1977. PubMed ID: 31517532
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of Type II LRRK2 inhibitors on signaling and mitophagy.
    Tasegian A; Singh F; Ganley IG; Reith AD; Alessi DR
    Biochem J; 2021 Oct; 478(19):3555-3573. PubMed ID: 34515301
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The G2019S mutation in LRRK2 imparts resiliency to kinase inhibition.
    Kelly K; Wang S; Boddu R; Liu Z; Moukha-Chafiq O; Augelli-Szafran C; West AB
    Exp Neurol; 2018 Nov; 309():1-13. PubMed ID: 30048714
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structure-Based Virtual Screening and De Novo Design to Identify Submicromolar Inhibitors of G2019S Mutant of Leucine-Rich Repeat Kinase 2.
    Park H; Kim T; Kim K; Jang A; Hong S
    Int J Mol Sci; 2022 Oct; 23(21):. PubMed ID: 36361616
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dopaminergic neurodegeneration induced by Parkinson's disease-linked G2019S LRRK2 is dependent on kinase and GTPase activity.
    Nguyen APT; Tsika E; Kelly K; Levine N; Chen X; West AB; Boularand S; Barneoud P; Moore DJ
    Proc Natl Acad Sci U S A; 2020 Jul; 117(29):17296-17307. PubMed ID: 32631998
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular insights of the G2019S substitution in LRRK2 kinase domain associated with Parkinson's disease: A molecular dynamics simulation approach.
    Agrahari AK; Doss GPC; Siva R; Magesh R; Zayed H
    J Theor Biol; 2019 May; 469():163-171. PubMed ID: 30844370
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exploring the functional impact of mutational drift in LRRK2 gene and identification of specific inhibitors for the treatment of Parkinson disease.
    Nagarajan N; Chellam J; Kannan RR
    J Cell Biochem; 2018 Jun; 119(6):4878-4889. PubMed ID: 29369408
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Virtual Screening and Biological Activity Evaluation of New Potent Inhibitors Targeting LRRK2 Kinase Domain.
    Tan S; Gong X; Liu H; Yao X
    ACS Chem Neurosci; 2021 Sep; 12(17):3214-3224. PubMed ID: 34387082
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Leucine-rich repeat kinase 2 inhibitors: a patent review (2006 - 2011).
    Deng X; Choi HG; Buhrlage SJ; Gray NS
    Expert Opin Ther Pat; 2012 Dec; 22(12):1415-26. PubMed ID: 23126385
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Altered Development of Synapse Structure and Function in Striatum Caused by Parkinson's Disease-Linked LRRK2-G2019S Mutation.
    Matikainen-Ankney BA; Kezunovic N; Mesias RE; Tian Y; Williams FM; Huntley GW; Benson DL
    J Neurosci; 2016 Jul; 36(27):7128-41. PubMed ID: 27383589
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Roc, the G-domain of the Parkinson's disease-associated protein LRRK2.
    Park Y; Liao J; Hoang QQ
    Trends Biochem Sci; 2022 Dec; 47(12):1038-1047. PubMed ID: 35840518
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.